This product is a humanized CDR-grafted antibody targeting hemagglutinin of H5N1 influenza virus, derived from mH5M9 murine antibody. The antibody hH5F9 reacts with the epitope (aa 234-241) of HA. This antibody is extensive in application prospect in prevention and treatment and vaccine design of the avian influenza H5N1 in the future.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-078 | Recombinant Anti-IAV HA VHH Single Domain Antibody | FC, CA, IP, FuncS | Llama VHH |
HPAB-0344CQ | Recombinant Llama Anti-IAV HA Single Domain Antibody (HPAB-0344CQ) | ELISA, Neut | Llama VHH |
HPAB-0345CQ | Recombinant Llama Anti-IAV HA Single Domain Antibody (HPAB-0345CQ) | ELISA, Neut | Llama VHH |
There are currently no Customer reviews or questions for HPAB-0113-WJ-S(P). Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.